Literature DB >> 30989564

The efficacy and safety of immunosuppressive agents plus steroids compared with steroids alone in the treatment of Henoch-Schönlein purpura nephritis: A meta-analysis.

Jiaxing Tan1,2, Yi Tang1, Zhengxia Zhong1,2, Siyu Yan2, Li Tan1,2, Padamata Tarun2, Wei Qin3.   

Abstract

BACKGROUND: Henoch-Schönlein purpura nephritis (HSPN) is the most severe symptom of Henoch-Schönlein purpura. The role of immunosuppressive agents combined with steroids is controversial in treating HSPN. Our meta-analysis was performed to assess the efficacy and safety of the combined therapy in the treatment of HSPN compared with steroids alone.
METHODS: Cochrane Library, Pubmed, Embase, and Web of Science were searched and Newcastle-Ottawa Scale was used to assess the quality of the literatures. Odds ratios (OR) and standard mean difference (SMD) with a 95% confidence interval (CI) were used for dichotomous and continuous variables. A random-effect model or fixed-effect analysis was applied according to heterogeneity.
RESULTS: A total of 9 articles were selected in our study. HSPN patients treated with combined therapy demonstrated a significant increase in complete remission rates (OR = 1.95; 95% CI 1.17-3.23, P = 0.010) and total remission rates (OR = 2.30 95% CI 1.33-3.98, P = 0.003) when compared with steroids alone. Children seemed to benefit more from combined treatment (OR = 2.45; CI 1.20-5.02, P = 0.014) than adults (OR = 1.56; CI 0.76-3.20, P = 0.225). Additionally, immunosuppressants plus steroids had an advantage on decreasing proteinuria (SMD = 0.28; CI 0.05-0.52, P = 0.019) and increasing the level of serum albumin (SMD = 0.98; CI 0.35-1.60, P = 0.002). However, significant differences were not found in the estimated glomerular filtration rate (eGFR) and rates of side-effects.
CONCLUSION: Administration of immunosuppressive agents combined with steroids may be a superior alternative for HSPN. Nevertheless, long-term, high-quality, large-sample, and multicenter RCTs are required to make the results more convincing.

Entities:  

Keywords:  HSPN; Henoch–Schönlein purpura nephritis; Immunosuppressive agents; Meta-analysis; Steroids

Year:  2019        PMID: 30989564     DOI: 10.1007/s11255-019-02092-7

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  5 in total

1.  Safety and Efficacy Evaluation of Traditional Chinese Medicine (Qingre-Lishi-Yishen Formula) Based on Treatment of Regular Glucocorticoid Combined with Cyclophosphamide Pulse in Children Suffered from Moderately Severe Henoch-Schonlein Purpura Nephritis with Nephrotic Proteinuria.

Authors:  Lirong Fan; Huimin Yan; Xiaofang Zhen; Xiaoming Wu; Jing Hao; Linyi Hou; Lei Han
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-27       Impact factor: 2.629

2.  Gastrointestinal Henoch-Schönlein purpura successfully treated with Mycophenolate Mofetil: Description of 2 case reports.

Authors:  Maria Francesca Gicchino; Dario Iafusco; Maria Maddalena Marrapodi; Rosa Melone; Giovanna Cuomo; Angela Zanfardino; Emanuele Miraglia Del Giudice; Alma Nunzia Olivieri
Journal:  Medicine (Baltimore)       Date:  2021-01-08       Impact factor: 1.817

Review 3.  Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis.

Authors:  Xuerong Yang; Qi Li; Yuanyuan He; Yulian Zhu; Rou Yang; Xiaoshi Zhu; Xi Zheng; Wei Xiong; Yong Yang
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

4.  Pulmonary embolism as the primary presentation of IgA vasculitis.

Authors:  Osama Mosalem; Nora Hernandez Garcilazo; Yehia Saleh; Fawzi Abu Rous
Journal:  BMJ Case Rep       Date:  2020-08-27

5.  Global Glomerulosclerosis and Segmental Glomerulosclerosis Could Serve as Effective Markers for Prognosis and Treatment of IgA Vasculitis With Nephritis.

Authors:  Jiaxing Tan; Yicong Xu; Zheng Jiang; Gaiqin Pei; Yi Tang; Li Tan; Zhengxia Zhong; Padamata Tarun; Wei Qin
Journal:  Front Med (Lausanne)       Date:  2020-10-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.